Distillate Capital Partners Portfolio holdings
Distillate Capital Partners is an ETF and separate-account manager that uses a model-based approach to pick only the stocks where quality and value overlap. It was founded in 2017 by Tom Cole, Matt Swanson and Jay Beidler, who had worked at Institutional Capital, UBS Global Asset Management and Brinson Partners. Cole, the firm's chief executive, was previously chief investment officer at Institutional Capital, a value investment firm. The founders concluded that traditional measures of value had lost their meaning, and built their stock selection on free-cash-flow measures instead. The firm is entirely employee-owned and offers separate accounts to institutions and high net worth individuals.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CME Group
CME
|
+$28.6M |
| 2 |
Intercontinental Exchange
ICE
|
+$28.1M |
| 3 |
Intuit
INTU
|
+$28M |
| 4 |
FedEx
FDX
|
+$25.3M |
| 5 |
Boston Scientific
BSX
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$32.7M |
| 2 |
AbbVie
ABBV
|
+$22.7M |
| 3 |
PACCAR
PCAR
|
+$20.5M |
| 4 |
Coterra Energy
CTRA
|
+$20.1M |
| 5 |
Emcor
EME
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.14% |
| 2 | Healthcare | 22.82% |
| 3 | Industrials | 12.35% |
| 4 | Consumer Discretionary | 11.36% |
| 5 | Financials | 10.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Merck
MRK
$362B
| $48.5M | 2.52% |
377,115
-69,800
| -16% | -$8.17M |
2025 Q1
5 quarters
|
|
2
Salesforce
CRM
$176B
| $43.5M | 2.26% |
277,708
+62,984
| +29% | +$11.1M |
2025 Q2
4 quarters
|
|
3
Comcast
CMCSA
$86.6B
| $40.8M | 2.12% |
1,683,566
+482,300
| +40% | +$12.4M |
2024 Q2
8 quarters
|
|
|
4
AbbVie
ABBV
$515B
| $38.9M | 2.03% |
154,783
-105,590
| -41% | -$22.7M |
2021 Q2
20 quarters
|
|
5
Uber
UBER
$140B
| $34.8M | 1.81% |
481,691
+5,442
| +1% | +$399K |
2025 Q2
4 quarters
|
|
6
Accenture
ACN
$154B
| $34.7M | 1.8% |
278,844
+121,399
| +77% | +$21.1M |
2025 Q3
3 quarters
|
|
7
Booking.com
BKNG
$119B
| $30.4M | 1.58% |
170,672
-30,478
| -15% | -$5.2M |
2024 Q1
9 quarters
|
|
8
Cigna
CI
$77.6B
| $29M | 1.51% |
105,193
-1,873
| -2% | -$529K |
2023 Q3
11 quarters
|
|
9
Altria Group
MO
$127B
| $28.9M | 1.5% |
402,218
-9,625
| -2% | -$672K |
2023 Q2
12 quarters
|
|
10
Marathon Petroleum
MPC
$101B
| $28.3M | 1.47% |
110,738
-4,020
| -4% | -$987K |
2025 Q1
5 quarters
|
|
11
T-Mobile US
TMUS
$172B
| $26.7M | 1.39% |
159,002
-18,572
| -10% | -$3.52M |
2024 Q4
6 quarters
|
|
12
Adobe
ADBE
$93.1B
| $26.3M | 1.37% |
128,449
+920
| +0.7% | +$218K |
2024 Q4
6 quarters
|
|
13
UnitedHealth
UNH
$353B
| $25.8M | 1.34% |
62,058
-4,022
| -6% | -$1.49M |
2026 Q1
1 quarter
|
|
14
Automatic Data Processing
ADP
$120B
| $25.6M | 1.33% |
114,168
+1,269
| +1% | +$271K |
2025 Q3
3 quarters
|
|
15
Abbott
ABT
$190B
| $24M | 1.25% |
263,988
-18,975
| -7% | -$1.73M |
2026 Q1
1 quarter
|
|
16
Marsh
MRSH
$97.4B
| $23.2M | 1.21% |
139,177
+1,717
| +1% | +$287K |
2025 Q3
3 quarters
|
|
|
17
Intercontinental Exchange
ICE
$96.3B
| $23.1M | 1.2% |
+187,457
| New | +$28.1M |
2026 Q2
0 quarters
|
|
18
Arthur J. Gallagher & Co
AJG
$72.2B
| $23.1M | 1.2% |
100,446
+2,037
| +2% | +$433K |
2024 Q4
6 quarters
|
|
19
PayPal
PYPL
$49.2B
| $22.9M | 1.19% |
530,996
-4,584
| -0.9% | -$208K |
2023 Q1
13 quarters
|
|
|
20
CME Group
CME
$109B
| $22.9M | 1.19% |
+103,554
| New | +$28.6M |
2026 Q2
0 quarters
|
|
21
Global Payments
GPN
$25.8B
| $22.5M | 1.17% |
310,515
+78,922
| +34% | +$5.43M |
2025 Q4
2 quarters
|
|
22
Regeneron Pharmaceuticals
REGN
$93.6B
| $22.5M | 1.17% |
36,090
+7,520
| +26% | +$5.12M |
2024 Q4
6 quarters
|
|
23
Diamondback Energy
FANG
$50B
| $22.1M | 1.15% |
125,702
+5,422
| +5% | +$1.05M |
2021 Q2
20 quarters
|
|
24
Aon
AON
$71B
| $22M | 1.14% |
66,307
+756
| +1% | +$244K |
2026 Q1
1 quarter
|
|
|
25
FedEx
FDX
$72.2B
| $21.8M | 1.14% |
+69,729
| New | +$25.3M |
2026 Q2
0 quarters
|
|
Similar funds
Distillate Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Distillate Capital Partners held 145 positions worth $1.92B, up 1.3% from $1.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Distillate Capital Partners deployed $95.9M of net new capital in Q2 2026, opening 27 new positions and adding to 46 existing holdings. Its largest new stake was CME Group: 103,554 shares worth $22.9M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $22.7M trimmed.
- Distillate Capital Partners's largest Q2 2026 buy was CME Group: 103,554 shares worth $22.9M.
- Distillate Capital Partners added most to Accenture in Q2 2026, an estimated $21.1M increase.
- Distillate Capital Partners's biggest Q2 2026 reduction was AbbVie, cutting an estimated $22.7M.
- Distillate Capital Partners fully exited Qualcomm in Q2 2026, selling an estimated $32.7M.
- Distillate Capital Partners's ten largest holdings make up 19% of its $1.92B portfolio in Q2 2026.
- Distillate Capital Partners opened 27 new positions and closed 27 in Q2 2026.
- Distillate Capital Partners's portfolio value rose 1.3% quarter-over-quarter to $1.92B.
Based on Distillate Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.